gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · AQSTHealthcarePharmaceuticals

Aquestive Therapeutics, Inc. Common Stock (AQST)

$3.80−2.06%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$3.96▼ 38.91% in range
Nov 3, 2025Low $2.95 · High $6.62Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Aquestive Therapeutics closed at $3.80 on Nov 4, down 2.06%, 42.6% below its 52-week closing high. Volume of 3.3M shares was 1.50× its 20-day average (above normal).

Split-adjusted performance: -17.6% over one month, -10.2% over six months, -41.4% over one year.

In the quarter ended Jun 30, 2026, revenue was $13.82M, up 38.1% from a year earlier, with a net margin of -165.5%.

Short interest was 27.6M shares at the Oct 15 settlement, down 4.0% from the prior report (25.6% of float, 13.9 days to cover).

Market cap$476.9M125.5M shares
Revenue · quarter$13.8M+38.1% YoY
Diluted EPS$-0.18—
P/E · TTM—P/S 8.8×
Net margin-165.5%Gross 70.9%
Dividend yieldNone
52-week range2.95 – 6.62−42.6% from high
Volume3.3M1.50× 20-day avg
Volatility · 60d54.2%Annualised
Short % of float25.6%13.9 days to cover
Net cash$47.8MCash $98.5M
Next earnings—Not scheduled
Split-adjusted performance
1W −10.2%1M −17.6%3M −3.1%6M −10.2%YTD −41.2%1Y −41.4%3Y +151.7%5Y −24.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum64
Revenue growth75
Net margin40
Value (low P/E)—
Size60

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short27.6M−4.0% vs prior
Days to cover13.9Settled Oct 15
% of float25.6%
Short vol. 10d57.2%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
AQSTAquestive Therapeutics$3.80−2.06%−10.2%+38.1%−165.5%—$476.9M
GYREGyre Therapeutics$4.440.00%−44.8%−2.1%−40.1%—$470.8MCompare
ARVNArvinas$7.42+4.65%−27.7%+1014.7%67.8%52.2$485.2MCompare
MNPRMonopar Therapeutics$72.81+4.18%+14.0%———$488.7MCompare
PHATPhathom Pharmaceuticals$5.68−1.05%−55.2%+71.1%−16.4%—$461.7MCompare
EOLSEvolus$7.47+1.36%+18.2%+21.2%−9.6%—$493.4MCompare
RLMDRelmada Therapeutics$4.17−2.34%−46.9%———$444.8MCompare
CTMXCytomX Therapeutics$2.35+7.80%−43.1%−92.4%−1457.4%—$512.1MCompare
CBIOCrescent Biopharma$13.82+5.82%−23.5%———$513.4MCompare

News about Aquestive Therapeutics

All news →
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027GlobeNewswire Inc. · Oct 15, 2026▲ PositiveAQST DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action – AQSTGlobeNewswire Inc. · May 2, 2026▼ NegativeBragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Large Losses They Have Until Monday May 4th to Seek Lead Plaintiff RoleGlobeNewswire Inc. · Apr 30, 2026▼ NegativePortnoy Law Firm Announces Class Action on Behalf of Aquestive Therapeutics, Inc. InvestorsGlobeNewswire Inc. · Apr 28, 2026▼ NegativeBronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc. · Apr 27, 2026▼ Negative

Quick answers

What does Aquestive Therapeutics do?
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis.
What is AQST's market cap?
$476.94M, based on the Nov 4 close of $3.80.
Does Aquestive Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of AQST is sold short?
27.6M shares, 25.6% of float, as of Oct 15, 2026.
What sector is AQST in?
Healthcare, in the Pharmaceuticals industry.

About Aquestive Therapeutics

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

HQ: Warren, NJ147 employeesListed Jul 25, 2018aquestive.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology